




Stockholm3 test for early detection of Prostate Cancer

- **A comparison of Stockholm3, serum biomarkers, and risk calculators to predict prostate cancer in a diverse cohort: Evaluation of the Stockholm3 Multi-Ethnic SEPTA Trial**
- **Are we missing aggressive cancer with PSA screening alone? Biochemical recurrence after radical prostatectomy: Evidence from the STHLM3 trial**

Stockholm3 is a blood test for early detection of clinically significant prostate cancer in men aged 45–74 years, with a PSA level of 1.5 ng/ml, or greater, and no previous diagnosis of prostate cancer.

Key characteristics

- Increased early detection – increased sensitivity
- Increased specificity reduces over testing, unnecessary biopsies by 50% and treatment
- Higher accuracy compared to PSA, PSAD and prostate cancer risk calculator
- Can distinguish between aggressive and benign tumours in a way that PSA testing cannot
- Validated in combination with MRI and in multiple ethnicities
- Shown to detect clinically significant prostate cancers in PSA levels of 1.5–2.9 ng/ml
- Reduces healthcare costs



The Doctors Laboratory

The Halo Building
1 Mabledon Place
London WC1H 9AX

T 020 7307 7373 | E tdl@tdlpathology.com

tdlpathology.com/stockholm3